{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:21:32Z","timestamp":1789842092882,"version":"4.0.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010822","name":"Chengdu Science and Technology Bureau","doi-asserted-by":"crossref","award":["2021-YF05-00536-SN"],"award-info":[{"award-number":["2021-YF05-00536-SN"]}],"id":[{"id":"10.13039\/501100010822","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03770-w","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T16:32:54Z","timestamp":1742488374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessing the consistency of FIB-4, APRI, and GPR in evaluating significant liver fibrosis and cirrhosis in COVID-19 patients with concurrent liver diseases"],"prefix":"10.1186","volume":"25","author":[{"given":"Pan","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"3","key":"3770_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3748\/wjg.v29.i3.487","volume":"29","author":"MS Jeeyavudeen","year":"2023","unstructured":"Jeeyavudeen MS, Chaudhari R, Pappachan JM, Fouda S. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease. World J Gastroenterol. 2023;29(3):487\u2013502.","journal-title":"World J Gastroenterol"},{"key":"3770_CR2","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","volume":"55","author":"J Liu","year":"2020","unstructured":"Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, Xiong L, Guo C, Tian J, Luo J, Yao J, Pang R, Shen H, Peng C, Liu T, Zhang Q, Wu J, Xu L, Lu S, Wang B, Weng Z, Han C, Zhu H, Zhou R, Zhou H, Chen X, Ye P, Zhu B, Wang L, Zhou W, He S, He Y, Jie S, Wei P, Zhang J, Lu Y, Wang W, Zhang L, Li L, Zhou F, Wang J, Dittmer U, Lu M, Hu Y, Yang D, Zheng X. Longitudinal characteristics of lymphocyte responses andcytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.","journal-title":"EBioMedicine"},{"issue":"17","key":"3770_CR3","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.12998\/wjcc.v9.i17.4133","volume":"9","author":"M Ahmed","year":"2021","unstructured":"Ahmed M, Ahmed MH. Nonalcoholic fatty liver disease and COVID-19: an epidemic that begets pandemic. World J Clin Cases. 2021;9(17):4133\u201342.","journal-title":"World J Clin Cases"},{"issue":"8","key":"3770_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ijms18081649","volume":"18","author":"TE Adolph","year":"2017","unstructured":"Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017;18(8):1649.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3770_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00535-021-01760-9","volume":"56","author":"D Li","year":"2021","unstructured":"Li D, Ding X, Xie M, Tian D, Xia L. COVID-19-associated liver injury: Frombedside to bench. J Gastroenterol. 2021;56(3):218\u201330.","journal-title":"J Gastroenterol"},{"issue":"9","key":"3770_CR6","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1111\/liv.14601","volume":"40","author":"A Sonzogni","year":"2020","unstructured":"Sonzogni A, Previtali G, Seghezzi M, Grazia Alessio M, Gianatti A, Licini L, Morotti D, Zerbi P, Carsana L, Rossi R, Lauri E, Pellegrinelli A. Nebuloni m.liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020;40(9):2110\u20136.","journal-title":"Liver Int"},{"issue":"3","key":"3770_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jhep.2021.04.050","volume":"75","author":"MJ McConnell","year":"2021","unstructured":"McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee AI, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. J Hepatol. 2021;75(3):647\u201358.","journal-title":"J Hepatol"},{"issue":"4","key":"3770_CR8","first-page":"1367","volume":"94","author":"J Boeckmans","year":"2020","unstructured":"Boeckmans J, Rodrigues RM, Demuyser T, Pi\u00e9rard D, Vanhaecke T, Rogiers V. COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?Arch. Toxicol. 2020;94(4):1367\u20139.","journal-title":"Toxicol"},{"issue":"4","key":"3770_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420\u20132.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3770_CR10","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1093\/cid\/ciac014","volume":"75","author":"A Marrone","year":"2022","unstructured":"Marrone A, Nevola R, Sellitto A, Cozzolino D, Romano C, Cuomo G, Aprea C, Schwartzbaum MXP, Ricozzi C, Imbriani S, Rinaldi L, Gjeloshi K, Padula A, Ranieri R, Ruosi C, Meo LA, Abitabile M, Cinone F, Carusone C, Adinolfi LE. Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: A prospective controlled nonrandomized study. Clin Infect Dis. 2022;75(1):e403\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3770_CR11","doi-asserted-by":"publisher","first-page":"e0243700","DOI":"10.1371\/journal.pone.0243700","volume":"15","author":"R Galiero","year":"2020","unstructured":"Galiero R, Pafundi PC, Simeon V, Rinaldi L, Perrella A, Vetrano E, Caturano A, Alfano M, Beccia D, Nevola R, Marfella R, Sardu C, Coppola C, Scarano F, Maggi P, De Lucia Sposito P, Vocciante L, Rescigno C, Sbreglia C, Fraganza F, Parrella R, Romano A, Calabria G, Polverino B, Pagano A, Bologna C, Amitrano M, Esposito V, Coppola N, Maturo N, Adinolfi LE, Chiodini P, Sasso FC, COVOCA Study Group. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: findings from COVOCA study. PLoS ONE. 2020;15(12):e0243700.","journal-title":"PLoS ONE"},{"issue":"3","key":"3770_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jcmgh.2020.10.003","volume":"11","author":"DE Kleiner","year":"2021","unstructured":"Kleiner DE. Liver biopsy shines a light on COVID-19-Related liver injury. Cell Mol Gastroenterol Hepatol. 2021;11(3):881\u20132.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"3770_CR13","doi-asserted-by":"publisher","first-page":"916","DOI":"10.4254\/wjh.v13.i8.916","volume":"13","author":"P Anirvan","year":"2021","unstructured":"Anirvan P, Singh SP, Giammarino A, Satapathy SK. Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence. World J Hepatol. 2021;13(8):916\u201325.","journal-title":"World J Hepatol"},{"issue":"2","key":"3770_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jhep.2020.03.044","volume":"73","author":"D Ji","year":"2020","unstructured":"Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020;73(2):451\u20133.","journal-title":"J Hepatol"},{"issue":"2","key":"3770_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jfma.2020.08.019","volume":"120","author":"G Gheorghe","year":"2021","unstructured":"Gheorghe G, Bung\u0103u S, Ceobanu G, et al. The non-invasive assessment of hepatic fibrosis[J]. J Formos Med Assoc. 2021;120(2):794\u2013803.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"3770_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5152\/tjg.2018.17330","volume":"29","author":"MM Ayd\u0131n","year":"2018","unstructured":"Ayd\u0131n MM, Ak\u00e7al\u0131 KC. Liver fibrosis[J]. Turkish J Gastroenterol. 2018;29(1):14.","journal-title":"Turkish J Gastroenterol"},{"issue":"10","key":"3770_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis[J]. Nat Reviews Gastroenterol Hepatol. 2023;20(10):633\u201346.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"1","key":"3770_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.21672","volume":"46","author":"K Matsuzaki","year":"2007","unstructured":"Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor \u0392 signaling, promoting cirrhosis and hepatocellular carcinoma[J]. Hepatology. 2007;46(1):48\u201357.","journal-title":"Hepatology"},{"issue":"4","key":"3770_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jhep.2009.05.008","volume":"51","author":"B Bartosch","year":"2009","unstructured":"Bartosch B, Thimme R, Blum HE, et al. Hepatitis C virus-induced hepatocarcinogenesis[J]. J Hepatol. 2009;51(4):810\u201320.","journal-title":"J Hepatol"},{"issue":"1","key":"3770_CR20","doi-asserted-by":"publisher","first-page":"8867985","DOI":"10.1155\/2021\/8867985","volume":"2021","author":"A Michalak","year":"2021","unstructured":"Michalak A, Cicho\u017c-Lach H, Guz M, et al. Plateletcrit and mean platelet volume in the evaluation of alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients[J]. Biomed Res Int. 2021;2021(1):8867985.","journal-title":"Biomed Res Int"},{"issue":"8","key":"3770_CR21","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1136\/gutjnl-2020-321299","volume":"69","author":"J Neuberger","year":"2020","unstructured":"Neuberger J, Patel J, Caldwell H, et al. Guidelines on the use of liver biopsy in clinical practice from the British society of gastroenterology, the Royal college of radiologists and the Royal college of Pathology[J]. Gut. 2020;69(8):1382\u2013403.","journal-title":"Gut"},{"issue":"7","key":"3770_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","volume":"8","author":"MA Tincopa","year":"2023","unstructured":"Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Lancet Gastroenterol Hepatol. 2023;8(7):660\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"3770_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/jvh.12842","volume":"25","author":"DP Liu","year":"2018","unstructured":"Liu DP, Lu W, Zhang ZQ, et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B[J]. J Viral Hepatitis. 2018;25(5):581\u20139.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"3770_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/gutjnl-2016-311554","volume":"66","author":"M Lemoine","year":"2017","unstructured":"Lemoine M, Thursz M, Mallet V, Shimakawa Y. Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference. Gut. 2017;66(1):195\u20136.","journal-title":"Gut"},{"issue":"39","key":"3770_CR25","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.3748\/wjg.v26.i39.5919","volume":"26","author":"A Campos-Murgu\u00eda","year":"2020","unstructured":"Campos-Murgu\u00eda A, Ruiz-Marg\u00e1in A, Gonz\u00e1lez-Regueiro JA, Mac\u00edas-Rodr\u00edguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26(39):5919\u201343.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3770_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.36519\/idcm.2023.233","volume":"5","author":"B \u00c7opur","year":"2023","unstructured":"\u00c7opur B, S\u00fcrme S, Tun\u00e7er G, Bayramlar OF. The role of APRI, FIB-4, and SAD-60 scores as predictors of mortality in COVID-19 patients. Infect Dis Clin Microbiol. 2023;5(2):144\u201352.","journal-title":"Infect Dis Clin Microbiol"},{"issue":"17","key":"3770_CR27","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.3390\/jcm11175149","volume":"11","author":"ML Grigoras","year":"2022","unstructured":"Grigoras ML, Citu IM, Citu C, Chiriac VD, Gorun F, Levai MC, Manolescu D, Rosca O, Bratosin F, Gurumurthy S, Wulandari PH, Cretu OM. Evaluation of FIB-4, NFS, APRI and liver function tests as predictors for SARS-CoV-2 infection in the elderly population: A matched Case-Control analysis. J Clin Med. 2022;11(17):5149.","journal-title":"J Clin Med"},{"key":"3770_CR28","doi-asserted-by":"publisher","first-page":"829423","DOI":"10.3389\/fmed.2022.829423","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Liu F, Song T, Li Z, Xia P, Tang X, Xu M, Shen Y, Ma J, Liu X, Yu P. Liver fibrosis scores and clinical outcomes in patients with COVID-19. Front Med (Lausanne). 2022;9:829423.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"3770_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski S, Torriani M, Dieterich FJ, Thomas DT, Messinger DL, Nelson D. APRICOT clinical investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"5","key":"3770_CR30","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.29302","volume":"66","author":"G Xiao","year":"2017","unstructured":"Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486\u2013501.","journal-title":"Hepatology"},{"issue":"5","key":"3770_CR31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/hep.30842","volume":"70","author":"QM Anstee","year":"2019","unstructured":"Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology. 2019;70(5):1521\u201330.","journal-title":"Hepatology"},{"issue":"1","key":"3770_CR32","doi-asserted-by":"publisher","first-page":"e000288","DOI":"10.1136\/bmjgast-2019-000288","volume":"6","author":"KM Kolhe","year":"2019","unstructured":"Kolhe KM, Amarapurkar A, Parikh P, Chaubal A, Chauhan S, Khairnar H, Walke S, Ingle M, Pandey V, Shukla A. Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population. BMJ Open Gastroenterol. 2019;6(1):e000288.","journal-title":"BMJ Open Gastroenterol"},{"key":"3770_CR33","doi-asserted-by":"crossref","unstructured":"Ekin N, Ucmak F, Ebik B, Tugba Tuncel E, Kacmaz H, Arpa M, Engin Atay A, GPR. King\u2019s Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic Hepatitis B patients. Acta Gastroenterol Belg. 2022 Jan-Mar;85(1):62\u20138.","DOI":"10.51821\/85.1.9156"},{"issue":"5","key":"3770_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM. Age as a confounding factor for the accurate Non-Invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740\u201351.","journal-title":"Am J Gastroenterol"},{"key":"3770_CR35","doi-asserted-by":"publisher","first-page":"104912","DOI":"10.1016\/j.ebiom.2023.104912","volume":"99","author":"Z Chen","year":"2024","unstructured":"Chen Z, Tang W, Feng N, Lv M, Meng F, Wu H, Zhao Y, Xu H, Dai Y, Xue J, Wang J, Xu A, Zhang B, Chu D, Li Y, Wu D, Dong L, Zhang S, Xue R. Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective study. EBioMedicine. 2024;99:104912.","journal-title":"EBioMedicine"},{"issue":"23","key":"3770_CR36","doi-asserted-by":"publisher","first-page":"e20616","DOI":"10.1097\/MD.0000000000020616","volume":"99","author":"Q Li","year":"2020","unstructured":"Li Q, Huang C, Xu W, Hu Q, Chen L. Accuracy of fibroscan in analysis of liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease. Med (Baltim). 2020;99(23):e20616.","journal-title":"Med (Baltim)"},{"issue":"8","key":"3770_CR37","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1177\/2050640619865133","volume":"7","author":"K Staufer","year":"2019","unstructured":"Staufer K, Halilbasic E, Spindelboeck W, et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease[J]. United Eur Gastroenterol J. 2019;7(8):1113\u201323.","journal-title":"United Eur Gastroenterol J"},{"key":"3770_CR38","doi-asserted-by":"crossref","unstructured":"Released by National Health Commission of People\u2019s Republic of China & National Administration of Traditional Chinese Medicine on January 5. 2023. Diagnosis and treatment protocol for COVID-19 patients (Tentative 10th Version)[J]. Health Care Science, 2023, 2(1): 10\u201324.","DOI":"10.1002\/hcs2.36"},{"issue":"3","key":"3770_CR39","first-page":"195","volume":"26","author":"National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association","year":"2018","unstructured":"National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. [Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update]. Zhonghua Gan Zang Bing Za Zhi. 2018;26(3):195\u2013203.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"3770_CR40","unstructured":"Guidelines for the Prevention. Care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 Mar."},{"issue":"3","key":"3770_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.joim.2020.03.001","volume":"18","author":"LM Xu","year":"2020","unstructured":"Xu LM, Liu P. Hepatology committee of Chinese association of integrative medicine, China. Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition). J Integr Med. 2020;18(3):203\u201313.","journal-title":"J Integr Med"},{"key":"3770_CR42","doi-asserted-by":"crossref","unstructured":"Giovanna F, Flavia B,,Francesco D. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.[J]. J Hepatol 2008,48(2):335\u201352.","DOI":"10.1016\/j.jhep.2007.11.011"},{"issue":"2","key":"3770_CR43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology. 1996;24(2):289\u201393.","journal-title":"Hepatology"},{"issue":"7","key":"3770_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/jvh.12682","volume":"24","author":"MY Zhu","year":"2017","unstructured":"Zhu MY, Zou X, Li Q, et al. A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection[J]. J Viral Hepatitis. 2017;24(7):589\u201398.","journal-title":"J Viral Hepatitis"},{"issue":"39","key":"3770_CR45","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.3748\/wjg.v26.i39.5919","volume":"26","author":"A Campos-Murgu\u00eda","year":"2020","unstructured":"Campos-Murgu\u00eda A, Ruiz-Marg\u00e1in A, Gonz\u00e1lez-Regueiro JA, et al. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease[J]. World J Gastroenterol. 2020;26(39):5919.","journal-title":"World J Gastroenterol"},{"key":"3770_CR46","doi-asserted-by":"publisher","first-page":"28641","DOI":"10.18632\/oncotarget.16162","volume":"8","author":"Q Li","year":"2017","unstructured":"Li Q, Lu C, Li W, Huang Y, Chen L. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease. Oncotarget. 2017;8:28641\u20139.","journal-title":"Oncotarget"},{"issue":"8","key":"3770_CR47","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/gutjnl-2015-309260","volume":"65","author":"M Lemoine","year":"2016","unstructured":"Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut. 2016;65(8):1369\u201376.","journal-title":"Gut"},{"key":"3770_CR48","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00535-021-01782-3","volume":"56","author":"J Itakura","year":"2021","unstructured":"Itakura J, Kurosaki M, Setoyama H, et al. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis[J]. J Gastroenterol. 2021;56:470\u20138.","journal-title":"J Gastroenterol"},{"issue":"12","key":"3770_CR49","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s00535-019-01594-6","volume":"54","author":"L Wang","year":"2019","unstructured":"Wang L, Wang Y, Liu S, Zhai X, Zhou G, Lu F, Zhao J. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol. 2019;54(12):1096\u2013105.","journal-title":"J Gastroenterol"},{"issue":"1","key":"3770_CR50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10620-012-2343-9","volume":"58","author":"CM Chu","year":"2013","unstructured":"Chu CM, Lin DY, Liaw YF. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci. 2013;58(1):275\u201381.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3770_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jvh.12766","volume":"25","author":"RWH Hui","year":"2018","unstructured":"Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, Fung J, Wong DK, Lai CL, Yuen MF. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat. 2018;25(1):97\u2013104.","journal-title":"J Viral Hepat"},{"issue":"3","key":"3770_CR52","doi-asserted-by":"publisher","first-page":"e34198","DOI":"10.1371\/journal.pone.0034198","volume":"7","author":"X Jin","year":"2012","unstructured":"Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and Entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS ONE. 2012;7(3):e34198.","journal-title":"PLoS ONE"},{"issue":"4","key":"3770_CR53","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/liv.13271","volume":"37","author":"P Charatcharoenwitthaya","year":"2017","unstructured":"Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, Bhanthumkomol P, Bandidniyamanon W, Pausawasdi N, Tanwandee T. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int. 2017;37(4):542\u201351.","journal-title":"Liver Int"},{"issue":"4","key":"3770_CR54","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"LY Mak","year":"2020","unstructured":"Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, Yuen MF, Seto WK. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800\u20136.","journal-title":"J Hepatol"},{"issue":"10","key":"3770_CR55","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.dld.2016.06.001","volume":"48","author":"G Xiao","year":"2016","unstructured":"Xiao G, Zhu F, Wang M, Zhang H, Ye D, Yang J, Jiang L, Liu C, Yan L, Qin R. Diagnostic accuracy of APRI and FIB-4 for predicting hepatitis B virus-related liver fibrosis accompanied with hepatocellular carcinoma. Dig Liver Dis. 2016;48(10):1220\u20136.","journal-title":"Dig Liver Dis"},{"key":"3770_CR56","doi-asserted-by":"crossref","unstructured":"Mallet V, Dhalluin-Venier V, Roussin C, et al. The accuracy of the FIB\u20104 index for the diagnosis of mild fibrosis in chronic hepatitis B[J]. Volume 29. Alimentary pharmacology & therapeutics; 2009. pp. 409\u201315. 4.","DOI":"10.1111\/j.1365-2036.2008.03895.x"},{"issue":"7","key":"3770_CR57","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.gastrohep.2020.07.005","volume":"44","author":"CY Suarez-Quintero","year":"2021","unstructured":"Suarez-Quintero CY, Henao OP, Mu\u00f1oz-Velandia O. Concordancia Entre El resultado de La biopsia hep\u00e1tica y El \u00edndice APRI (Ast to platelet ratio Index) En El Diagn\u00f3stico de cirrosis En Pacientes Con Enfermedad hep\u00e1tica autoinmune[J]. Gastroenterolog\u00eda Y Hepatolog\u00eda. 2021;44(7):465\u201371.","journal-title":"Gastroenterolog\u00eda Y Hepatolog\u00eda"},{"issue":"7","key":"3770_CR58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.rce.2010.02.006","volume":"210","author":"JG Ib\u00e1\u00f1ez","year":"2010","unstructured":"Ib\u00e1\u00f1ez JG, P\u00e9rez M, Lamas JL, et al. Estudio de concordancia En El Grado de fibrosis hep\u00e1ticaestimada mediante Los \u00edndices bioqu\u00edmicos APRI y FORNS, y La Elastograf\u00eda de transici\u00f3n (Fibroscan\u00ae) En Pacientes coinfectados Por VIH-VHC[J]. Rev Clin Esp. 2010;210(7):317\u201322.","journal-title":"Rev Clin Esp"},{"key":"3770_CR59","doi-asserted-by":"crossref","unstructured":"Ekin N, U\u00e7mak F, Ebik B et al. GPR, King\u2019s score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic hepatitis B patients[J]. Acta Gastroenterol Belg, 2022, 85(1).","DOI":"10.51821\/85.1.9156"},{"issue":"2","key":"3770_CR60","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. 2021;41(2):261\u201370.","journal-title":"Liver Int"},{"issue":"2","key":"3770_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/qjmed\/hcy227","volume":"112","author":"WB Nseir","year":"2019","unstructured":"Nseir WB, Mograbi JM, Amara AE, et al. Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia[J]. QJM: Int J Med. 2019;112(2):95\u20139.","journal-title":"QJM: Int J Med"},{"issue":"1","key":"3770_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5501\/wjv.v12.i1.22","volume":"12","author":"RB Qi","year":"2023","unstructured":"Qi RB, Wu ZH. Association between COVID-19 and chronic liver disease: mechanism, diagnosis, damage, and treatment. World J Virol. 2023;12(1):22\u20139.","journal-title":"World J Virol"},{"issue":"11","key":"3770_CR63","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1111\/liv.13860","volume":"38","author":"CH Lee","year":"2018","unstructured":"Lee CH, Choi SH, Chung GE, et al. Nonalcoholic fatty liver disease is associated with decreased lung function[J]. Liver Int. 2018;38(11):2091\u2013100.","journal-title":"Liver Int"},{"issue":"8","key":"3770_CR64","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3851\/IMP3382","volume":"25","author":"SA Alqahtani","year":"2020","unstructured":"Alqahtani SA, Buti M. COVID-19 and hepatitis B infection[J]. Antivir Ther. 2020;25(8):389\u201397.","journal-title":"Antivir Ther"},{"key":"3770_CR65","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.12659\/MSM.906250","volume":"24","author":"Q He","year":"2018","unstructured":"He Q, Song X, Huang Y, et al. Dexamethasone stimulates hepatitis B virus (HBV) replication through autophagy[J]. Med Sci Monitor: Int Med J Experimental Clin Res. 2018;24:4617.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"issue":"19","key":"3770_CR66","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.12998\/wjcc.v9.i19.5266","volume":"9","author":"YF Wu","year":"2021","unstructured":"Wu YF, Yu WJ, Jiang YH, Chen Y, Zhang B, Zhen RB, Zhang JT, Wang YP, Li Q, Xu F, Shi YJ, Li XP. COVID-19 or treatment associated immunosuppression May trigger hepatitis B virus reactivation: A case report. World J Clin Cases. 2021;9(19):5266\u20139.","journal-title":"World J Clin Cases"},{"issue":"8","key":"3770_CR67","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/gutjnl-2020-321611","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness fromCOVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores[J]. Gut. 2020;69(8):1545\u20137.","journal-title":"Gut"},{"issue":"1","key":"3770_CR68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12985-023-02081-4","volume":"20","author":"Z Liu","year":"2023","unstructured":"Liu Z, Song L, Chen J, et al. Causal associations between chronic hepatitis B and COVID-19 in East Asian populations[J]. Virol J. 2023;20(1):109.","journal-title":"Virol J"},{"key":"3770_CR69","doi-asserted-by":"publisher","first-page":"736109","DOI":"10.3389\/fmed.2021.736109","volume":"8","author":"D Liu","year":"2022","unstructured":"Liu D, Zheng Y, Kang J, Wang D, Bai L, Mao Y, Zha G, Tang H, Zhang R. Not only high number and specific comorbidities but also age are closely related to progression and poor prognosis in patients with COVID-19. Front Med (Lausanne). 2022;8:736109.","journal-title":"Front Med (Lausanne)"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03770-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T17:03:37Z","timestamp":1742576617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03770-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3770"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03770-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki ( helsinki\/). Ethical approval for this research was obtained from the Ethics Committee of the Public Health and Clinical Center of Chengdu (No.: PJ-K2020-26-01). The ethics committee\/institutional review board waived the requirement for written informed consent from the participants or their legal guardians\/next of kin due to the retrospective nature of the study, the use of anonymized data, and the provision of comprehensive verbal and written information to all patients regarding the study\u2019s purpose and potential implications. The study was conducted in accordance with local legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All of the participants understand that the information will be published without their child or ward\u2019s\/their relative\u2019s (circle as appropriate) name attached but that full anonymity cannot be guaranteed. All of the participants understand that the text and any pictures or videos published in the article will be freely available on the internet and may be seen by the general public. The pictures, videos and text may also appear on other websites or in print and may be translated into other languages or used for commercial purposes. All of the participants were offered the opportunity to read the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}